Testicular cancer is a rare type of malignancy, but it is the most common malignancy in young men (aged between 20 and 34 years). Furthermore, it is the number one cause of cancer deaths in men in their 20s and 30s. About 50,000 cases of testicular cancer occur worldwide every year. Unfortunately, an increase in the incidence of the disease has been observed over the past few decades worldwide.
Primary testicular cancer: If the cancer is not treated, it will continue to grow. It is one of the most curable cancers in men even when diagnosed after metastasis (spread to other parts of the body or lymph nodes when diagnosed).On an average, the ten year survival rate of all men diagnosed with testicular cancer is about 98% (98 out of 100 men live for at least 10 years after diagnosis). Studies on seminomas show that most cases with stage 1 and stage 2 testicular cancers are curable; more than 95% men with stage 1 seminoma are cured and about 85 to 90% of men with stage 2 seminoma are cured. Data on non-seminoma testicular cancer show that more than 95% of men with stage 1 non-seminoma testicular cancer can be cured and about 70% with stage 3 non-seminoma testicular cancer are cured.
Recurrent testicular cancer: According to studies, most recurrences (80−90%) occur in the first year and the majority of the remaining cases (10−20%) recur in the second year after treatment. Recurrence after 2 years of completion of the treatment is rare (only in about 5%). The rate of recurrence of testicular cancer, however, is rare as most men (> 90% of cases) are cured with initial treatment. Fortunately, most recurrences can be treated and cured with chemotherapy or radiotherapy. The duration of follow-up after initial treatment has not been adequately investigated. Consult your doctor to know your follow-up schedule after treatment for testicular cancer.